Assist. Prof. Dr. Mei-Lang Kung | Pharmacology | Women Researcher Award
Senior Assistant Research Fellow | Kaohsiung Veterans General Hospital | Taiwan
Dr. Mei-Lang Kung is a distinguished researcher and academic specializing in cancer biology, gene engineering, and phytochemical pharmacology. She currently serves as a Senior Assistant Research Fellow at the Department of Medical Education and Research, Kaohsiung Veterans General Hospital, and an Assistant Professor at Shu-Zen Junior College of Medicine and Management. With a strong background in molecular biology and nanomedicine, Dr. Kung has contributed significantly to innovative research in oncology and nanomaterials for medical applications.
Profile๐ค
Strengths for the Awardsโจ
-
Strong Academic Background ๐
- Dr. Mei-Lang Kung holds a Ph.D. in Biological Science from National Sun Yat-sen University (2012).
- Her dissertation focused on cancer cell migration and epithelial-mesenchymal transition, a highly relevant area in biomedical research.
-
Extensive Research Expertise ๐ฌ
- Her work spans multiple interdisciplinary fields, including cancer biology, gene engineering, phytochemical pharmacology, and green nanomaterials.
- These diverse skill sets enhance the impact of her research in translational medicine.
-
Significant Research Contributions ๐
- 21+ peer-reviewed publications in high-impact journals (SCI-indexed).
- Notable research on nanomedicine and cancer treatment strategies, contributing to innovative therapeutic approaches.
- Demonstrated leadership as a corresponding author in multiple studies, reflecting independent research capability.
-
Recognition & Awards ๐ฅ
- Best Poster Award (2021) from the Taiwan Urology Association.
- National Taiwan University System Young Scholars Award (2018) for innovative research.
- Multiple Outstanding Paper Awards at prestigious conferences (IEEE, New Advance in Medicine, etc.).
- These accolades highlight her excellence in research and scholarly impact.
Education ๐
Dr. Kung earned her Ph.D. in Biological Science from National Sun Yat-sen University, Kaohsiung, Taiwan, in 2012, under the guidance of Prof. Tai Ming-Hong. Her dissertation focused on the mechanisms of hepatoma-derived growth factor-mediated cell migration and epithelial-mesenchymal transition. She also holds an M.S. in Biochemistry from Kaohsiung Medical University (2002) and a B.S. in Nutrition from Chung Shan Medical University (2000).
Experience ๐
Dr. Kung has extensive experience in academia and research. Since 2019, she has been a Senior Assistant Research Fellow at Kaohsiung Veterans General Hospital. She also holds a faculty position at Shu-Zen Junior College of Medicine and Management. Previously, she served as an Assistant Faculty member (2017-2019) and a Postdoctoral Research Associate (2012-2017) in the Chemistry Department of National Sun Yat-sen University, working under Dr. Shuchen Hsieh.
Research Interests On Pharmacology ๐
Dr. Kung’s research interests include cancer biology, gene engineering, phytochemical pharmacology, and toxicology. She is particularly focused on the development and applications of green nanomaterials for cancer treatment. Her work explores novel phytochemically derived nanoparticles and their effects on cancer cell adhesion, proliferation, and metastasis.
Awards ๐
- 2021: Taiwan Urology Association “Best Academic Activity Award – Best Poster Award”
- 2018: National Taiwan University System Young Scholars Selection for Innovative Research and Development Achievements – Excellent Work Award
- 2015: New Advance in Generation Medicine, Cancer and Stem Cell Outstanding Paper Award
- 2013: IEEE Nanotechnology Materials and Devices Conference, Outstanding Paper Award
Publications ๐ฐ
Dr. Kung has authored numerous peer-reviewed publications in high-impact journals. Below are some of her notable works:
- Wang, J.-H., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2025). “Nanosized ginger-derived phenolic zingerone obstructs cell cycle G2/M progression and initiates apoptosis in human colorectal cancer.” Environmental Toxicology. DOI:10.1002/tox.24470 (SCI; 2023 IF=4.4)
- Chu, L.-W., Chen, J.-Y., Chen, Y.-W., Hsieh, S., & Kung, M.-L.* (2024). “Phytoconstituent-derived zingerone nanoparticles disrupt cell adhesion and suppress cell motility in melanoma B16F10 cells.” Journal of Biotechnology. DOI:10.1016/j.jbiotec.2024.06.015
- Kung, M.-L., Cheng, S. M., Wang, Y.-H., et al.* (2024). “Deficiency of RNA adenosine deaminase (ADAR2) ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in male diet-induced obese mice.” Communications Biology. (SCI; 2022 IF=5.9)
- Kung, M.-L., Yang, T.-H., Lin, C.-C., et al.* (2024). “ADAR2 deficiency ameliorates nonalcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.” Journal of Cachexia, Sarcopenia and Muscle. DOI:10.1002/jcsm.13460 (SCI; 2022 IF=8.9)
- Hu, T.-H., Wu, J.-C., Huang, S.-T., et al.* (2023). “HDGF Stimulates Liver Tumorigenesis by Enhancing Reactive Oxygen Species Generation in Mitochondria.” Journal of Biological Chemistry. (SCI; 2022 IF=4.8)
Conclusion ๐
Dr. Mei-Lang Kung has made remarkable contributions to cancer research and nanomedicine, with a strong emphasis on translating scientific discoveries into therapeutic applications. Her expertise in molecular oncology and green nanotechnology continues to impact the scientific community, making her a leader in the field of biomedical research. Through her innovative work, she strives to advance cancer treatment strategies and improve patient outcomes.